Thi Thuong Lan VO, Bich Thuan TA, Dieu Linh VUONG, Quynh Uyen NGUYEN, Van To TA

Promoter methylation profile of GSTP1 and RASSF1A in prostate cancerand benign hyperplasia in Vietnamese men

Background/aim: The GSTP1 and RASSF1A methylations that were considered as prostate cancer-specific molecular biomarkers have been extensively reported in Western/American patients with prostate cancer but are rarely reported in Southeast Asian patients. In the present study, the methylation status of the GSTP1 and RASSF1A promoters was evaluated in prostate cancer (PCa) and benign prostate hyperplasia (BPH) tissues from Vietnamese men. Materials and methods: The accuracy of methylation-specific polymerase chain reaction (MSP) was validated to analyze the methylation pattern of GSTP1 and RASSF1A in 59 PCa and 37 BPH patients, respectively. The methylation status was confirmed by the sequencing of cloned MSP products. The association between methylation status and the clinical and pathological parameters of tumors was statistically analyzed. Results: The methylation of GSTP1 and RASSF1A was detected in 39/59 and 19/59 PCa patients and in 4/37 and 10/37 BPH patients, respectively. The methylation frequency of GSTP1 was significantly associated with PCa (P < 0.01). The RASSF1A methylation frequency (32.2%) observed in the study was lower relative to that detected in other populations. Conclusions:GSTP1 and RASSF1A methylation was accurately detected using the validated MSP method and can be used as a biomarker to diagnose prostate cancer.

PDF

___

1. Jamel A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 18931907.
2. Venderbos LD, Roobol MJ. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl 2011; 13: 219224.
3. Esserman LJ, Thompson IM, Reid B. Over diagnosis and over treatment in cancer: an opportunity for improvement. JAMA 2013; 310: 797798.
4. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605613.
5. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010; 2: 1733.
6. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:1227.
7. Maxwell A, McCudden CR, Wians F, Monte S, Willis MS. Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples. Lab Med 2009; 40: 171178.
8. Majumdar S, Buckles E, Estrada J, Koochekpour S. Aberrant DNA methylation and prostate cancer. Cur Genomics 2011; 12: 486505.
9. Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman F. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res 2008; 6: 843850.
10. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Criekinge WV. The epigenetic promise for prostate cancer diagnosis. Prostate 2012; 72: 12481261.
11. Yoon HY, Kim YW, Kang HW, Kim WT, Yun SJ, Lee SC, Kim WJ, Kim YJ. DNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysis. Korean J Urol 2012; 53: 200 205.
12. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Mho S. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 2011; 105: 6573.
13. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogenes 2001; 20: 35633577.
14. Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, Mo C, Qiu S. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and Meta-analysis. PLoS ONE 2013; 8: e75283.
15. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 2007; 13: 2541 2548.
16. Rabiau N, Thiam MO, Satih S, Guy L, Kemeny JL, Boiteux JL, Fontana L, Bignon YJ, Bernard-Gallon D. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009; 23: 387392.
17. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker ST, Martinez SR, Singer FR, Hoon DSB. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009; 55: 559567.
18. Addo BK, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16: 35393547.
19. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protocol 2006; 1: 23552364.
20. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogen 2005; 159: 114122.
21. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514519.
22. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate. Am J Pathol 2003; 163: 923933.
23. Esteller M, Corn PG, Drena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 45154518.
24. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9: 26732677.
25. Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 2013; 33: 191197.
26. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21: 68356840.
27. Vardi A, Bosviel R, Rabiau N, Adjakly M, Satih S, Dechelotte P, Boiteux J, Fontana L, Bignon YJ, Guy L et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 2010; 24: 393400.
28. Lan TV, Ha TN, Uyen QN, Duong TN, Huong TN, Thuan BT, Duong PA, To VT. Standardization of the methylation-specific PCR method for analysing BRCA1 and ER methylation. Mol Med Reports 2014; 9: 18441850.
29. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucl Acids Res 2007; 35: e41.
30. Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 2010; 5: e9359.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. P Natl Acad Sci USA 1996; 93: 9821 9826.
32. Kristensen LS, Hansen L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009; 55: 14711483.
33. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007; 211: 269277.
34. Syeed N, Sameer AS, Hamid A, Shah ZA, Afroze D, Rasool R, Siddiqi MA. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep 2010; 3: 883 887.
35. Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin. ISRN Urology 2013; 2013: 627249.
36. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 84728478.
37. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20: 645653.
38. Ge YZ, Xu LW, Jia RP, Xu Z, Feng YM, Wu R, Yu P, Zhao Y, Gui ZL, Tan SJ et al. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumor Biol 2014; 35: 38813890.
39. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2008; 179: 529535.